Ascendis Pharma A/S reports developments as a global biopharmaceutical company applying its TransCon technology platform to new therapies in endocrinology, rare disease and oncology. News commonly centers on TransCon CNP, also known as navepegritide, including YUVIWEL for pediatric achondroplasia, as well as TransCon hGH combination data and growth-disorder clinical programs.
Recurring company updates also include financial results and business updates, U.S. regulatory and commercialization milestones, patient-access programs, and capital-structure actions such as convertible senior note activity. Corporate news also documents the completed transition from American Depositary Shares to ordinary shares trading on Nasdaq under ASND.
Ascendis Pharma (ASND) will present hypoparathyroidism and achondroplasia program updates at ASBMR 2026 in Boston on October 9–12, 2026.
Combined data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials show normalization of bone mass and microarchitecture over five years in patients treated with palopegteriparatide. Achondroplasia presentations cover improved growth and physical functioning with navepegritide in the ApproaCH open-label extension, where participants know their treatment, and continued improvements in lower-limb alignment at Week 104. Another presentation will cover 78-week results from the Phase 2 COACH trial of navepegritide combined with lonapegsomatropin.
Ascendis Pharma (ASND) will regain exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity, following the effectiveness of a previously announced termination of its collaboration with Novo Nordisk.
After termination, all licenses granted to Novo Nordisk in these areas, including for once-monthly TransCon Semaglutide, revert fully to Ascendis and neither party has ongoing financial obligations to the other. Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications, and to advance once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide, as a potential treatment for obesity and type 2 diabetes. The company intends to apply its TransCon platform and “algorithm for product innovation” to pursue therapies it believes may have best-in-class potential.
Ascendis Pharma (ASND) announced that its board has authorized a share repurchase program for up to $400 million of the company’s ordinary shares.
Repurchases may be executed from time to time, in amounts management deems appropriate, using methods such as open market purchases, privately negotiated transactions, block trades, accelerated share repurchases, and 10b5-1 trading plans, or a combination of these. The timing and size of buybacks will depend on factors including market conditions and share price. The authorization does not obligate Ascendis to repurchase any specific number of shares and may be modified, suspended, or terminated at any time without notice.
Ascendis Pharma (ASND) reported 52-week data from the open-label sentinel cohort of the pivotal Phase 2 reACHin trial of once-weekly TransCon CNP (navepegritide) in seven treatment-naïve infants aged 0 to <2 years with achondroplasia.
All children showed stable or improved Achondroplasia Foramen Magnum Score (AFMS), with a mean increase in sagittal foramen magnum diameter of +3.15 mm and no decompression surgeries over 52 weeks. Linear growth improved, with a mean change in ACH-specific supine length Z-score of +0.42 and mean annualized growth velocity of 9.9 cm/year. Pharmacokinetics were comparable to those observed in older children, supporting the 100 μg/kg/week dose.
TransCon CNP was generally well tolerated, with no injection site reactions, deaths, fractures, bone-related safety events, symptomatic hypotension, treatment-related adverse events, or treatment disruptions or discontinuations reported in this cohort.
Ascendis Pharma (ASND) will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 8:30 a.m. Eastern Time in New York.
The live presentation will be accessible via a webcast in the Investors & News section of the Ascendis Pharma website, with a replay available there for 30 days after the event. Ascendis Pharma is a global biopharmaceutical company focused on applying its TransCon technology platform to develop therapies addressing unmet medical needs, with headquarters in Copenhagen and additional facilities in Europe and the United States.
Ascendis Pharma (ASND) will present new data from its Endocrinology Rare Disease programs at ESPE 2026 in Marseille, France, from September 8-10, 2026.
The company highlights a podium presentation of first sentinel cohort data from the pivotal reACHin trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to <2 years. Additional presentations cover hypoparathyroidism patient-reported outcomes and growth hormone indications, including the HighLiGHts phase 3 trial design of lonapegsomatropin in children with several short-stature conditions and a systematic literature review on pediatric growth hormone deficiency prevalence.
Ascendis Pharma (Nasdaq: ASND) entered a binding term sheet with BioMarin for a global settlement and license covering YUVIWEL (navepegritide) and related products. BioMarin will grant Ascendis a non-exclusive, worldwide, royalty-bearing license and waive certain regulatory rights, dismiss proceedings, and provide a covenant not to sue on covered IP.
Ascendis will dismiss its proceedings and pay BioMarin royalties on net sales of navepegritide products of 20% in the United States and 18% in the EU, South Korea, and Brazil from first commercial sale in each country through May 20, 2030. Ascendis reiterated expectations of more than €500 million operating cash flow in 2026 and a potential €5 billion revenue in 2030.
Ascendis Pharma (Nasdaq: ASND) will present Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia at the ISDS 2026 meeting in Toronto, held August 26–29, 2026. The oral presentation, titled “Improved Growth and Physical Functioning in Children with Achondroplasia Treated with Navepegritide in the ApproaCH Trial Open-Label Extension,” is scheduled for Friday, August 28, 10:00–10:15 a.m., and will be delivered by Carlos Bacino, M.D.
Ascendis will also present a poster analyzing number needed to harm for injection site reactions when indirect treatment comparison is not suitable. TransCon CNP (marketed as YUVIWEL) received U.S. FDA approval in February 2026 for increasing linear growth in certain pediatric achondroplasia patients, and its Marketing Authorisation Application is under review by the European Medicines Agency, with a decision expected in the fourth quarter of 2026.
Ascendis Pharma (Nasdaq: ASND) reported Q2 2026 total product revenue of €315 million, up 105% year over year, led by YORVIPATH with €252 million, SKYTROFA with €55 million, and YUVIWEL with €8 million. Total revenue reached €339 million.
Operating profit was €220 million (65% margin), versus a €53 million operating loss a year earlier, driven by product revenue growth and sale of a Rare Pediatric Disease Priority Review Voucher for €158 million net. Net profit was €207 million, or €2.83 per diluted share; non-IFRS net profit was €61 million.
Cash and cash equivalents rose to €812 million, including €56 million used for share repurchases and RSU settlements. Ascendis completed the optional redemption and conversion of all $575 million 2.25% Convertible Senior Notes due 2028, settling €719 million of related liabilities to equity, and was added to multiple Russell U.S. Indexes.
Ascendis Pharma (Nasdaq: ASND) will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before U.S. market open. The company will host a conference call and live webcast at 8:00 a.m. Eastern Time, with access and a 30‑day replay available via the Investors & News section of its website.